Copyright
©The Author(s) 2019.
World J Gastrointest Oncol. Apr 15, 2019; 11(4): 310-321
Published online Apr 15, 2019. doi: 10.4251/wjgo.v11.i4.310
Published online Apr 15, 2019. doi: 10.4251/wjgo.v11.i4.310
Table 3 The rates of symptom recurrence, stent restenosis and survival during follow-up
| TIPS-125I group | TIPS only group | P-value | |
| Rate of stent stenosis | < 0.05 | ||
| 6 mo | 12.5 | 42.2 | |
| 12 mo | 27.5 | 68.9 | |
| 24 mo | 42.5 | 84.4 | |
| Rate of symptom recurrence | < 0.05 | ||
| 6 mo | 7.5 | 31.1 | |
| 12 mo | 22.5 | 62.2 | |
| 24 mo | 35 | 82.2 | |
| Survival rate | < 0.05 | ||
| 6 mo | 80 | 64.4 | |
| 12 mo | 45 | 24.4 | |
| 24 mo | 20 | 4.4 |
- Citation: Zhang Y, Wu YF, Yue ZD, Zhao HW, Wang L, Fan ZH, He FL, Wang T, Liu FQ. Iodine-125 implantation with transjugular intrahepatic portosystemic shunt for main portal vein tumor thrombus. World J Gastrointest Oncol 2019; 11(4): 310-321
- URL: https://www.wjgnet.com/1948-5204/full/v11/i4/310.htm
- DOI: https://dx.doi.org/10.4251/wjgo.v11.i4.310